HER2-positive metastatic breast cancer: New agents on the horizon

Hong Kong Journal of Radiology

Volumn 15, Issue 4 SUPPL., 2012, Pages 51-56

  Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antineoplastic agents; Breast neoplasms; Hormone replacement therapy

Indexed keywords

AFATINIB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; NAVELBINE; NERATINIB; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADJUVANT THERAPY; BREAST METASTASIS; CARDIOTOXICITY; CONSTIPATION; DIARRHEA; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 84875046037     PISSN: 22236619     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
2. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265-74. (Pubitemid 46207001)
3. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicentre phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21:2889-95.
4. Gelmon KA, Boyle F, Kaufman B, Huntsman D, Manikhas A, Di Leo A, et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919 [abstract]. J Clin Oncol. 2012;30(Suppl):LBA671.
5. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43. (Pubitemid 46021510)
6. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27:1999-2006.
7. von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273-81.
8. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-30.
9. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463-75.
10. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-19.
11. Blackwell KL, Miles D, Gianni L, Gianni L, Krop IE, Welslau M, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane [abstract]. J Clin Oncol. 2012;30(Suppl):LBA1.
12. Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab plus docetaxel in previously untreated HER2-positive metastatic breast cancer [abstract]. ECCO-ESMO 2011;5001.
13. Diéras V, Harbeck N, Albain K, Burris HA III, Awada A, Crivellari D, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer interim efficacy and safety results [abstract]. Proceedings of the 33rd Annual San Antonio Breast Cancer Symposium, 2010 Dec 8-12; San Antonio, Texas: P3-14-01.
14. Ellis PA, Barrios CH, Im Y, Patre M, Branle F, Perez A, et al. MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2011;29(Suppl):TPS102.
15. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869-78.
16. Rimawi MF, Aleixo SB, Rozas AA, Matos Neto JN, Caleffi M, Vinholes JJ, et al. A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC) [abstract]. J Clin Oncol. 2012;30(Suppl):S606.
17. Harbeck N, Im SA, Huang CS, Im YH, Xu BH, Hurvitz SA, et al. LUX-breast 1: randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment [abstract]. J Clin Oncol. 2012;30(Suppl):TPS649.
18. Hickish T, Tseng LM, Mehta AO, Tsang J, Kovalenko N, Udovitsa D, et al. LUX-breast 2: phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L) [abstract]. J Clin Oncol. 2012;30(Suppl):TPS651.
19. Joensuu H, Kaci MO. LUX-breast 3: randomized phase II study of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy [abstract]. J Clin Oncol. 2012;30(Suppl):TPS647.
20. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28:1301-7.
21. Hurvitz SA, Andre F, Burris HA, Toi M, Buyse ME, Sahmoud T, et al. BOLERO-1: a randomized, phase III, double-blind, placebo-controlled multicentre trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive, locally advanced or metastatic breast cancer (BC) [abstract]. J Clin Oncol. 2012;30(Suppl): TPS648.